A Bioelectronic Medicine Company
advancing the treatment of autoimmune disease symptoms.
About Us
Boomerang Medical is on a mission to disrupt the treatment of bowel urgency symptoms in patients with ulcerative colitis (UC). The company is developing a bioelectric neuromodulation technology, which has been granted Breakthrough Device Designation by the FDA, currently being evaluated in an FDA-approved clinical trial studying ulcerative colitis at leading Inflammatory Bowel Disease (IBD) centers in the US.
Our Focus
IBD is one of the most debilitating autoimmune diseases, affecting millions globally. Living with IBD impacts not just physical health, but also work, relationships, and well-being. Current treatments include medications and surgery, but the complexity of the condition means that there is always room for innovative approaches.
What if the next big leap in managing IBD symptoms is already hardwired into our bodies? That's the question propelling our focus on neuromodulation, a promising frontier in bioelectronic medicine.
Boomerang Medical is dedicated to promoting IBD awareness and education. We are proud to be a member of the Crohn’s & Colitis Foundation's Corporate Circle.
Boomerang Medical is headquartered in the heart of Silicon Valley on the campus of El Camino Hospital in Mountain View, California. We are proud to be a Company–In-Residence at the prestigious Fogarty Innovation incubator–the only healthcare-focused incubator of its kind in the US–giving us access to the brightest minds and expertise in the medical technology industry.
Meet the Team
Chief Executive Officer
Tom Shehab, MD
Tom practiced medicine for 15 years as a gastroenterologist and he brings his experience as a physician, healthcare executive, and investor focused on medical device and health IT companies to Boomerang Medical. He serves on the boards of Endogenex, Motif Neurotech, and Virtual Incision, and previously led Arboretum’s investment in nVision Medical.
.png)
Co-Founder, Chief Technology Officer
David Miller, MEng
David is an innovator and entrepreneur, holding more than 50 patents spanning diverse technologies and clinical applications. With over 20 years of experience, David has co-founded multiple companies, is a Stanford BioDesign Fellow, and was previously a Distinguished Scientist and Technical Fellow at Medtronic.
Vice President, Therapy Development
Lucas Payne
Lucas has 20+ years of experience leveraging his passion for patient care, HCP training and entrepreneurship to advance Class III medical device innovation for companies such as Johnson & Johnson and Abbott. Lucas began his career in the medical field in patient care as a radiation technologist.
Vice President, Clinical & Regulatory
Bruce Van Deman
Bruce is a clinical research and medical sciences executive with extensive experience leading clinical trials, regulatory strategy, evidence generation and physician engagement across medical technology companies. He has held senior leadership roles at Medtronic, Edwards Lifesciences, NeoChord and Conformal Medical, supporting pivotal studies, product development, reimbursement and commercialization.
Senior Director, Clinical Strategy and Safety
Colleen Holthe
Colleen has a deep understanding of clinical research and regulatory affairs within the medical device industry. She holds 20+ years of experience conducting 25 clinical trials and a proven track record of leading Class III medical device trials from inception to FDA approval.
Senior Director, Clinical Therapy Development
Malea D'Amico, CCRA, CCRP
Malea has spent 21 years on the front lines of clinical research in over 70 medtech and biotech clinical trials. An expert in clinical study quality assurance, her experience crosses all phases clinical trials including benchwork, QA, monitoring, field support and patient outreach.
Board of Directors + Advisors
Boomerang Medical is proud to be a portfolio company of
Arboretum Ventures and Hatteras Venture Partners, as well as a
Company-In-Residence at Fogarty Innovation.
Tom Shehab, MD
Arboretum Ventures
Managing Partner
Andrew Cleeland
Fogarty Innovation
Chief Executive Officer
Jeff Terrell
Arboretum Ventures
General Partner
Gayle Kuokka
Fogarty Innovation
Chief Financial Officer
Lauren Flickinger
Hatteras Venture Partners
General Partner
John Morriss
Fogarty Innovation
Director of Innovation Acceleration
Scientific Advisors
Peter Irving, MA, MD, FRCP
Co-PI of BOOM-IBD2 Pivotal Trial
Guy’s and St Thomas’ NHS Foundation Trust
Consultant Gastroenterologist
Kings College London
Professor of Inflammatory Bowel Disease
Edward Barnes, MD, MPH
Co-PI of BOOM-IBD2 Pivotal Trial
University of North Carolina at Chapel Hill
Associate Professor of Medicine,
Co-Director of Multidisciplinary IBD Center
Corey A. Siegel, MD, MS
Laura Raffals, MD
Warren Grill, PhD
Chief Scientific Advisor
Scientific Advisory Board Member
Scientific Advisor
Dartmouth-Hitchcock Medical Center
Section Chief of Gastroenterology and Hepatology, Co-Director of the IBD Center
Duke University
James B. Duke Distinguished Professor of Biomedical Engineering at Duke University
Mayo Clinic
Professor of Medicine, Department of Medicine Associate Chair of Faculty Development, Vice Chair of the Division of Gastroenterology & Hepatology
Boomerang Medical in the News
Good Girl Greta: What the Body Was Saying All Along
Columbia Surgery I May 13, 2026
On a recent afternoon, not long after she crossed into her second trimester, filmmaker Rachel Ross found herself doing something she hadn’t been able to do in years: walking through New York without planning every exit.
Business Wire | Sept 4, 2025
Trial evaluates neuromodulation for ulcerative colitis, the most common form of IBD.
How a New Clinical Trial for IBD Is Changing Frank's Life
Columbia Surgery I October 13, 2024
Frank Soldano's life has been a rollercoaster of medical challenges, resilience, and hope. For over two decades, he has battled the debilitating effects of inflammatory bowel disease...